AR110282A1 - Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 - Google Patents

Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1

Info

Publication number
AR110282A1
AR110282A1 ARP170103343A ARP170103343A AR110282A1 AR 110282 A1 AR110282 A1 AR 110282A1 AR P170103343 A ARP170103343 A AR P170103343A AR P170103343 A ARP170103343 A AR P170103343A AR 110282 A1 AR110282 A1 AR 110282A1
Authority
AR
Argentina
Prior art keywords
ring
group
alkoxy
cycloalkyl
alkyl
Prior art date
Application number
ARP170103343A
Other languages
English (en)
Inventor
Huifen Chen
Guiling Zhao
Gregory Hamilton
Snahel Patel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR110282A1 publication Critical patent/AR110282A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Composiciones farmacéuticas que incluyen los compuestos y uso de los compuestos en el tratamiento de enfermedades mediadas por la inhibición de la RIP1 quinasa. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable de éste, en donde R¹ y R²: (a) son seleccionados cada uno independientemente entre el grupo que consiste en alquilo C₁₋₆, cicloalquilo C₃₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, tioalquilo C₁₋₆, alquilo C₁₋₆-N(RN)₂, fenilo, heteroarilo de 5 a 6 miembros y heterociclilo de 4 a 5 miembros; (b) junto con el N de amida adyacente, forman un anillo heterocíclico insaturado de 4 a 7 miembros opcionalmente sustituido por uno o dos R³, en donde el anillo heterocíclico insaturado contiene cero o un heteroátomo adicional seleccionado entre el grupo que consiste en NRN, O y S; o (c) junto con el N de amida adyacente, forma una parte de heteroarilo bicíclica opcionalmente sustituida por uno o dos R³, en donde la parte heterocíclica bicíclica contiene cero a tres heteroátomos adicionales seleccionados entre el grupo que consiste en N, O y S, en donde sólo uno de los heteroátomos adicionales es O ó S; cada R³ es seleccionado independientemente entre el grupo que consiste en F, Cl, alquilo C₁₋₆, cicloalquilo C₃₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, hidroxialquilo C₁₋₆ y fenoxi; o, cuando R¹ y R² junto con el N de amida adyacente forman un anillo de 6 miembros, dos R³ pueden formar juntos un puente de 1 a 2 carbonos o un espirocicloalquilo C₃₋₅; cada RN es seleccionado independientemente entre el grupo que consiste en H, alquilo C₁₋₆, cicloalquilo C₃₋₆, alcoxi C₁₋₆ y haloalquilo C₁₋₆; o dos RN junto con el N adyacente forman un anillo de 4 a 6 miembros; el anillo A es un heteroarilo de 5 ó 6 miembros que tiene 1 a 3 heteroátomos seleccionados entre el grupo que consiste en nitrógeno, oxígeno y azufre; en donde el anillo A es opcionalmente sustituido con 1 a 2 sustituyentes seleccionados entre el grupo que consiste en halógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆ y haloalcoxi C₁₋₆; y en donde si un átomo de nitrógeno en el anillo A es sustituido, el sustituyente no es halógeno, alcoxi C₁₋₆ o haloalcoxi C₁₋₆ que tiene un átomo de oxígeno o azufre unido directamente al átomo de nitrógeno; el anillo B es un cicloalquilo de 5 a 7 miembros o un heterociclilo de 5 a 7 miembros que tiene 1 a 3 heteroátomos seleccionados entre el grupo que consiste en nitrógeno, oxígeno y azufre; en donde el anillo B es sustituido de acuerdo con (a), (b) o ambos (a) y (b): (a) 1 a 2 sustituyentes seleccionados entre el grupo que consiste en halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, tioalquilo C₁₋₆, alquilo C₁₋₆-N(RN)₂ y ciano; en donde si un átomo de nitrógeno es sustituido en el anillo B, el sustituyente no es halógeno, ciano o un alcoxi C₁₋₆, haloalcoxi C₁₋₆ o tioalquilo C₁₋₆ que tiene un átomo de oxígeno o azufre unido directamente al átomo de nitrógeno; en donde dos sustituyentes en el anillo B juntos pueden formar un puente de 1 a 2 carbonos o un grupo espirocicloalquilo C₃₋₅; (b) 1 sustituyente seleccionado entre el grupo que consiste en fenilo, bencilo, CH₂-(cicloalquilo C₃₋₆) y CH₂CH₂-(cicloalquilo C₃₋₆), CH₂-(heterociclilo de 4 a 6 miembros), CH₂CH₂-(heterociclilo de 4 a 6 miembros), heteroarilo de 5 ó 6 miembros y CH₂-(heteroarilo de 5 ó 6 miembros); en donde cuando un anillo fenilo está presente éste puede ser sustituido por 1 ó 2 sustituyentes seleccionados entre el grupo que consiste en halógeno, alquilo C₁₋₄, haloalquilo C₁₋₄, alcoxi C₁₋₄, haloalcoxi C₁₋₄ y ciano; siempre que si el anillo B es sustituido por un solo sustituyente, éste no es halógeno o metilo.
ARP170103343A 2016-12-02 2017-11-30 Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 AR110282A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662429558P 2016-12-02 2016-12-02

Publications (1)

Publication Number Publication Date
AR110282A1 true AR110282A1 (es) 2019-03-13

Family

ID=60569907

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103343A AR110282A1 (es) 2016-12-02 2017-11-30 Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1

Country Status (7)

Country Link
US (2) US11071721B2 (es)
EP (1) EP3548484A1 (es)
JP (1) JP6890179B2 (es)
CN (1) CN110023313B (es)
AR (1) AR110282A1 (es)
TW (1) TW201831478A (es)
WO (1) WO2018100070A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110023313B (zh) * 2016-12-02 2022-10-25 豪夫迈·罗氏有限公司 二环酰胺化合物及其使用方法
EP3652178B1 (en) 2017-07-14 2024-01-24 F. Hoffmann-La Roche AG Bicyclic ketone compounds and methods of use thereof
CA3078688A1 (en) 2017-10-31 2019-05-09 F. Hoffmann-La Roche Ag Bicyclic sulfones and sulfoxides and methods of use thereof
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
CN115605463A (zh) 2019-09-27 2023-01-13 德州大学系统董事会（Us） 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂
BR112022010082A2 (pt) 2019-11-26 2022-08-30 Univ Texas Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
CN112552339A (zh) * 2020-12-10 2021-03-26 安徽昊帆生物有限公司 一种o-二苯基磷酰羟胺的制备方法
WO2022212809A1 (en) * 2021-04-02 2022-10-06 Genentech, Inc. Processes for making bicyclic ketone compounds

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620508A1 (de) 1965-07-23 1969-09-18 Thomae Gmbh Dr K Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3948903A (en) * 1972-12-15 1976-04-06 Parke, Davis & Company Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8610530D0 (en) 1986-04-30 1986-06-04 Fbc Ltd Herbicides
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
AU8071698A (en) 1997-06-13 1998-12-30 Sugen, Inc. Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction
EP1254115A2 (en) 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
PL382706A1 (pl) * 2002-08-26 2007-11-26 Takeda Pharmaceutical Company Limited Związek modulujący receptor wapnia i jego zastosowanie
WO2004050062A2 (en) 2002-12-03 2004-06-17 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
US7432379B2 (en) 2003-05-02 2008-10-07 Elan Pharmaceuticals, Inc. Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
US20090018902A1 (en) * 2007-07-09 2009-01-15 Jannine Miller Commuter credits system and method
EP2083009A1 (de) * 2008-01-22 2009-07-29 Grünenthal GmbH Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN104105697B (zh) * 2011-11-03 2016-11-09 霍夫曼-拉罗奇有限公司 二环哌嗪化合物
TWI648273B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（三）
CN105473554B (zh) 2013-07-10 2019-08-13 沃泰克斯药物股份有限公司 作为离子通道调节剂的稠合的哌啶酰胺类
EA032357B1 (ru) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
KR20170042595A (ko) * 2014-08-21 2017-04-19 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 의약으로서의 rip1 키나제 억제제로서의 헤테로시클릭 아미드
CA2988601C (en) 2015-07-02 2021-12-07 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
WO2017096301A1 (en) 2015-12-04 2017-06-08 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1)
WO2017109724A1 (en) 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
SG10201913587WA (en) 2016-02-05 2020-02-27 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1
CN110023313B (zh) 2016-12-02 2022-10-25 豪夫迈·罗氏有限公司 二环酰胺化合物及其使用方法
US11072607B2 (en) * 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
EP3652178B1 (en) * 2017-07-14 2024-01-24 F. Hoffmann-La Roche AG Bicyclic ketone compounds and methods of use thereof
RU2020114670A (ru) 2017-10-11 2021-11-12 Ф. Хоффманн-Ля Рош Аг Бициклические соединения для применения в качестве ингибиторов rip1 киназы
CA3078688A1 (en) 2017-10-31 2019-05-09 F. Hoffmann-La Roche Ag Bicyclic sulfones and sulfoxides and methods of use thereof

Also Published As

Publication number Publication date
EP3548484A1 (en) 2019-10-09
JP6890179B2 (ja) 2021-06-18
TW201831478A (zh) 2018-09-01
US11607396B2 (en) 2023-03-21
US20220339129A1 (en) 2022-10-27
CN110023313B (zh) 2022-10-25
JP2019534312A (ja) 2019-11-28
CN110023313A (zh) 2019-07-16
US20180153831A1 (en) 2018-06-07
WO2018100070A1 (en) 2018-06-07
US11071721B2 (en) 2021-07-27

Similar Documents

Publication Publication Date Title
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
AR109958A1 (es) Lactamas bicíclicas de piridona y sus métodos de uso
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
AR099367A1 (es) Inhibidores de la tirosina quinasa de bruton
JP2016536364A5 (es)
AR089865A1 (es) Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR095312A1 (es) Compuestos de biarilamida como inhibidores de cinasa
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR095430A1 (es) Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR112274A1 (es) Compuestos bicíclicos de cetona y sus métodos de uso
AR109650A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR092288A1 (es) Ligandos del receptor ep1
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento
AR104512A1 (es) Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap)

Legal Events

Date Code Title Description
FB Suspension of granting procedure